Lido Advisors’s Immunocore IMCR Stock Holding History

Lido Advisors’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-8,126	Closed	-$255K	–	1867
2025 Q2	$255K	Buy	+8,126	New	+$252K	﹤0.01%	1413

Other funds holding IMCR

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Lido Advisors's IMCR Position: Q3 2025 in Review

Lido Advisors sold out of Immunocore (IMCR) in Q3 2025, closing a stake of 8,126 shares — an estimated $255K sold.

Lido Advisors first reported a position in IMCR in Q2 2025 and held it in 1 quarter. The position peaked at $255K in Q2 2025. 132 funds tracked by Wall St. Rank hold IMCR as of Q3 2025.

Lido Advisors reported no remaining Immunocore position as of Q3 2025 after selling out during the quarter.
Lido Advisors sold 8,126 Immunocore shares in Q3 2025, an estimated $255K.
Lido Advisors first reported a position in Immunocore in Q2 2025 and held it in 1 quarter.
Lido Advisors's Immunocore position peaked at $255K in Q2 2025.
132 funds tracked by Wall St. Rank held Immunocore as of Q3 2025.

Based on Lido Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.